Brian Wiley

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA

Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.